NICM
CPRX

Neo Ivy Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Neo Ivy Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-78,530
Closed -$1.83M – 371
2025
Q4 		$1.83M Buy
78,530
+57,314
+270% +$1.28M 0.29% 126
2025
Q3 		$418K Sell
21,216
-104,411
-83% -$2.15M 0.1% 248
2025
Q2 		$2.73M Buy
+125,627
New +$2.97M 0.87% 20
2025
Q1 		– Sell
-35,652
Closed -$744K – 311
2024
Q4 		$744K Buy
+35,652
New +$766K 0.15% 160

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Neo Ivy Capital Management's CPRX Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 78,530 shares — an estimated $1.83M sold.

Neo Ivy Capital Management first reported a position in CPRX in Q4 2024 and held it in 4 quarters. The position peaked at $2.73M in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Neo Ivy Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 78,530 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.83M.
  • Neo Ivy Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 4 quarters.
  • Neo Ivy Capital Management's Catalyst Pharmaceutical position peaked at $2.73M in Q2 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.